Terns Pharmaceuticals Inc (TERN) Directors and Executive Officers

Officers & Directors

Executives:

1. Amy Burroughs - Chief Executive Officer and Director (Principal Executive Officer)
2. Mark Vignola - Chief Financial Officer (Principal Financial and Accounting Officer)

Board of Directors:

1. David Fellows - Chairman of the Board of Directors
2. Jill Quigley - Director
3. Jeffrey Kindler - Director
4. Hongbo Lu - Director
5. Carl Gordon - Director
6. Radhika Tripuraneni - Director
7. Ann Taylor - Director
8. Amy Burroughs - Director ,

Terns Pharmaceuticals Inc currently has 59 employees.

News about Terns Pharmaceuticals Inc Key Personnel

Empowering Transformation: Terns Pharmaceuticals Strengthens Leadership Team for Future Success.

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
FOSTER CITY, Calif., July 29, 2024 - Terns Pharmaceuticals, a leading clinical-stage biopharmaceutical company focused on developing small-molecule product candidates to tackle critical diseases such as oncology and obesity, announced today the appointment of Elona Kogan, Esq., as their new Chief Legal Officer. The company also revealed that they will soon undergo a transition in the role of Chief Financial Officer (CFO). These developments showcase Terns commitment to enhancing their leadership team and positioning the company for sustained success.
Elona Kogan s appointment mar...

Steered by Fresh Leadership, Terns Pharmaceuticals Commits to Revolutionizing Treatment Paradigms for Serious Diseases

Terns Pharmaceuticals Undergoes Leadership Changes as it Navigates the Path to Addressing Serious Diseases
FOSTER CITY, Calif., May 08, 2024 - Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company with a focus on developing small-molecule product candidates to tackle severe diseases such as oncology and obesity, has announced significant leadership changes. The company has appointed Scott Harris as the new Chief Development Officer (CDO), effective May 28, 2024. Concurrently, the current President and Head of Research and Development, Dr. Erin Quirk, will be leaving the position on June 3, 2024, to explore alternative opportunities.
Terns Pharmaceuticals has been at t...